Episode Overview

In this episode recorded live at Longevity Fest 2025, host Dr. Lexi Gonzales and co-host Jessica Carter are joined by Dr. Kiran Krishnan, a research microbiologist and expert on the human microbiome. The conversation challenges the traditional "wait and see" approach to liver health, arguing that relying on elevated enzymes means waiting until damage has already occurred. Krishnan explains the critical link between the liver and the gut microbiome, introduces new biomarkers for early detection, and discusses the formulation logic behind Dose, a functional liver support product.

Key Discussion Points

• Functional vs. Traditional Views: Traditional medicine often ignores liver health until enzymes (AST/ALT) rise, which indicates cellular damage. Functional medicine views the liver through a systems biology lens, focusing on performance before pathology.

• The Lag in Markers: AST and ALT are "lagging indicators," often appearing two stages after dysfunction begins. The liver can suffer from fatty deposition (steatosis) and toxicity while maintaining normal enzyme levels.

• The Gut-Liver Cycle: There is a bidirectional relationship between the liver and gut. A compromised liver produces a smaller bile acid pool, leading to uncontrolled microbial overgrowth (SIBO) because bile is antimicrobial and activates FXR receptors. Conversely, a leaky gut sends endotoxins (LPS) directly to the liver.

• "Borrowed Science" in Supplements: Many liver supplements include ingredients like milk thistle based on general reputation but fail to conduct studies on their specific finished formulation. This leads to issues with bioavailability and genetic identification of herbs.

• Foundational Health: The liver is the primary supplier of glucose to the brain and activator of thyroid hormones. Treating hormones or fatigue without addressing the liver is often ineffective.

Actionable Insights for Practitioners

• Update Your Lab Panels: Do not rely solely on AST/ALT. Look for early performance markers such as elevated VLDL (early insulin resistance), LBP (LPS Binding Protein, indicating toxic load), and HDL3 (a marker of toxin elimination).

• Monitor HOMA-IR: Prioritize HOMA-IR over A1C. The liver is the first organ to dysfunction during insulin resistance, and HOMA-IR detects this stress much earlier than A1C.

• Rethink Turmeric Formulations: When treating systemic inflammation, black pepper (piperine) is useful. However, for liver support, avoid black pepper. You want the liver to capture and metabolize the curcuminoids rather than bypassing the organ.

• Screen for SIBO: If a patient has SIBO, assume liver dysfunction. Studies show a ~68% prevalence of SIBO in fatty liver patients compared to ~12% in the general population.

Featured Resources & Calls to Action

• Product: Dose – A liquid-shot liver support formulation validated by finished-product studies.

• Call to Action: Visit the Innovations in Clinical Implementation landing page for further deep dives into the research mentioned.

Analogies for Understanding

• The "Heart Attack" Standard: Dr. Krishnan argues that waiting for liver enzymes (AST/ALT) to rise is a failure of preventive care. He compares it to other organs: "We wouldn't wait for dementia symptoms to care for the brain... [or] wait till you have some beta amyloid plaque before we start really thinking about your brain health".

The "Topless Beach" (Microbial Overgrowth): To describe what happens in the small intestine when bile flow is low, Krishnan uses a vivid metaphor: without bile to keep them in check, microbes view the gut as "Miami... a topless beach." It is warm, there are nutrients (food), and they run wild because the "police" (bile) aren't there to stop them.